Literature DB >> 25194335

Utility of serum IgG, IgG4 and carbonic anhydrase II antibodies in distinguishing autoimmune pancreatitis from pancreatic cancer and chronic pancreatitis.

Renata Talar-Wojnarowska1, Anita Gąsiorowska2, Marek Olakowski3, Daria Dranka-Bojarowska3, Paweł Lampe3, Jacek Śmigielski4, Magdalena Kujawiak5, Janina Grzegorczyk5, Ewa Małecka-Panas2.   

Abstract

PURPOSE: Autoimmune pancreatitis (AIP) can mimic pancreatic cancer in its clinical presentation, imaging features and laboratory parameters. The aim of our study was to compare IgG, IgG4 and anti-CAIIAb serum levels in patients with AIP, pancreatic adenocarcinoma (PA) and chronic pancreatitis (CP) and to assess their clinical significance and utility in differential diagnosis of pancreatic diseases. PATIENT/
METHODS: The study included 124 patients: 45 with PA, 24 with AIP and 55 with CP. Peripheral venous blood samples were obtained from all analyzed patients at the time of hospital admission and total IgG, IgG4 and anti-CAIIAB serum levels were measured using ELISA tests.
RESULTS: Serum levels of IgG, IgG4 and anti-CAIIAb were significantly higher in patients with AIP compared to PA and CP patients (p<0.001). In AIP patients the median IgG levels were 19.7 g/l, IgG4 levels - 301.9 mg/dl and anti-CAIIAb - 81.82 ng/ml, compared to 10.61 g/l, 123.2mg/dl and 28.6 ng/ml, respectively, in PA patients. IgG4 for the cut-off 210 mg/dl showed the best sensitivity and specificity (83.8% and 89.5%) in AIP diagnosis compared to IgG (69.3% and 87.3%, respectively) and anti-CAIIAb (45.3% and 74.3%). However, 16 (35.5%) patients with PA and 14 (25.4%) patients with CP had IgG4 levels greater than 140 mg/dl. Moreover, in 3 (6.67%) patients with pancreatic cancer those values were greater than 280 mg/dl. No patients with CP had IgG4 more than 280 mg/dl.
CONCLUSIONS: IgG4 at cut-off 210 mg/dl showed the best sensitivity and specificity in AIP diagnosis compared to IgG and anti-CAIIAb, however elevations of serum IgG4 may be seen in subjects without AIP, including pancreatic cancer.
Copyright © 2014 Medical University of Bialystok. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.

Entities:  

Keywords:  Autoimmune pancreatitis; Carbonic anhydrase II (CAII); Chronic pancreatitis; IgG; IgG4; Pancreatic adenocarcinoma

Mesh:

Substances:

Year:  2014        PMID: 25194335     DOI: 10.1016/j.advms.2014.08.003

Source DB:  PubMed          Journal:  Adv Med Sci        ISSN: 1896-1126            Impact factor:   3.287


  5 in total

1.  Rare case of Helicobacter pylori-positive multiorgan IgG4-related disease and gastric cancer.

Authors:  Min Li; Qiang Zhou; Kun Yang; David R Brigstock; Lu Zhang; Ming Xiu; Li Sun; Run-Ping Gao
Journal:  World J Gastroenterol       Date:  2015-03-21       Impact factor: 5.742

2.  Outcome and Genetic Factors in IgG4-Associated Autoimmune Pancreatitis and Cholangitis: A Single Center Experience.

Authors:  Matthias Buechter; Paul Manka; Falko Markus Heinemann; Monika Lindemann; Benjamin Juntermanns; Ali Canbay; Guido Gerken; Alisan Kahraman
Journal:  Gastroenterol Res Pract       Date:  2017-03-02       Impact factor: 2.260

Review 3.  The Clinical Utility of Soluble Serum Biomarkers in Autoimmune Pancreatitis: A Systematic Review.

Authors:  Ana Dugic; Cristina Verdejo Gil; Claudia Mellenthin; Miroslav Vujasinovic; J-Matthias Löhr; Steffen Mühldorfer
Journal:  Biomedicines       Date:  2022-06-26

Review 4.  A systematic review of serum autoantibodies as biomarkers for pancreatic cancer detection.

Authors:  Karin Dumstrei; Hongda Chen; Hermann Brenner
Journal:  Oncotarget       Date:  2016-03-08

5.  Serum Immunoglobulin G Is Associated With Decreased Risk of Pancreatic Cancer in the Swedish AMORIS Study.

Authors:  Sam Sollie; Aida Santaolalla; Dominique S Michaud; Debashis Sarker; Sophia N Karagiannis; Debra H Josephs; Niklas Hammar; Goran Walldius; Hans Garmo; Lars Holmberg; Ingmar Jungner; Mieke Van Hemelrijck
Journal:  Front Oncol       Date:  2020-02-28       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.